We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $3B
1-Year Est. Return 46.72%
This Fund
S&P 500
This Quarter Est. Return
+10.55%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
+$446M
Cap. Flow
-$654M
Cap. Flow %
-19.4%
Top 10 Hldgs %
44.1%
Holding
79
New
25
Increased
8
Reduced
18
Closed
6

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$95M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$56.3M
3
HNGE
Hinge Health
HNGE
+$47.6M
4
INSP icon
Inspire Medical Systems
INSP
+$36.6M
5
CDNA icon
CareDx
CDNA
+$31.1M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$78.1M
2
GH icon
Guardant Health
GH
+$43.6M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$38.1M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
5
KRYS icon
Krystal Biotech
KRYS
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 73.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
26
Dianthus Therapeutics
DNTH
$5.68B
$32.9M 0.98%
+835,057
New +$21.3M
CDNA icon
27
CareDx
CDNA
$1.92B
$31.7M 0.94%
+2,182,781
New +$31.1M
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$11.5B
$28.6M 0.85%
+528,000
New +$30.2M
GMED icon
29
Globus Medical
GMED
$10.4B
$28.5M 0.85%
498,000
+250,800
+101% +$14.4M
ORKA
30
Oruka Therapeutics
ORKA
$5.56B
$26.6M 0.79%
1,382,350
-142,492
-9% -$2.11M
RGEN icon
31
Repligen
RGEN
$7.44B
$26.2M 0.78%
195,656
+51,100
+35% +$6.21M
KNSA icon
32
Kiniksa Pharmaceuticals
KNSA
$4.83B
$25M 0.74%
643,180
-459,400
-42% -$14.9M
THC icon
33
Tenet Healthcare
THC
$20.1B
$24.7M 0.73%
+121,700
New +$21.6M
MRVI icon
34
Maravai LifeSciences
MRVI
$997M
$24M 0.71%
8,353,287
– –
EXAS
35
DELISTED
Exact Sciences
EXAS
$22.7M 0.67%
+414,600
New +$20.7M
AKRO
36
DELISTED
Akero Therapeutics
AKRO
$22.6M 0.67%
+475,400
New +$23M
ATEC icon
37
Alphatec Holdings
ATEC
$1.27B
$22M 0.65%
1,514,604
-2,120,568
-58% -$29.5M
KIDS icon
38
OrthoPediatrics
KIDS
$485M
$20.5M 0.61%
1,107,770
– –
VKTX icon
39
Viking Therapeutics
VKTX
$4.04B
$20M 0.59%
759,455
-678,100
-47% -$20.2M
CSTL icon
40
Castle Biosciences
CSTL
$749M
$18.7M 0.56%
822,735
– –
DRUG
41
Bright Minds Biosciences
DRUG
$700M
$18.4M 0.55%
+303,685
New +$11.8M
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.65B
$17.7M 0.53%
+588,700
New +$17.7M
HROW icon
43
Harrow
HROW
$1.43B
$16.5M 0.49%
342,391
-529,855
-61% -$20M
SRPT icon
44
Sarepta Therapeutics
SRPT
$1.66B
$16M 0.48%
+832,100
New +$14.8M
KYMR icon
45
Kymera Therapeutics
KYMR
$9.1B
$15.7M 0.46%
+276,692
New +$12.5M
ENGN icon
46
enGene Therapeutics
ENGN
$122M
$15.5M 0.46%
+2,266,319
New +$10.3M
DAWN
47
DELISTED
Day One Biopharmaceuticals
DAWN
$15.4M 0.46%
2,181,598
– –
CLDX icon
48
Celldex Therapeutics
CLDX
$2.77B
$15.3M 0.45%
+591,689
New +$13.7M
XNCR icon
49
Xencor
XNCR
$1.44B
$14.6M 0.43%
1,246,280
-409,410
-25% -$3.55M
RNAM
50
DELISTED
Avidity Biosciences
RNAM
$14.5M 0.43%
+331,907
New +$13.4M
1
2
3

Similar funds

NC
NZS Capital Denver, Colorado $3B AUM 21.29% 1-Year Est. Return
SGI
Swan Global Investments Durango, Colorado $3B AUM 15.66% 1-Year Est. Return
SP
SurgoCap Partners New York $2.99B AUM 39.34% 1-Year Est. Return
DIG
Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3B AUM 24.41% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Braidwell's Q3 2025 Portfolio in Review

As of Q3 2025, Braidwell held 79 positions worth $3.37B, up 15% from $2.92B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Braidwell withdrew a net $654M in Q3 2025, closing 6 positions and reducing 18 holdings. Its most notable exit was Guardant Health, an estimated $43.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 72% a quarter earlier.

Against the trend, Braidwell opened a new position in Soleno Therapeutics worth $86.7M.

  • Braidwell's largest Q3 2025 buy was Soleno Therapeutics: 1,281,989 shares worth $86.7M.
  • Braidwell added most to Inspire Medical Systems in Q3 2025, an estimated $36.6M increase.
  • Braidwell's biggest Q3 2025 reduction was argenx, cutting an estimated $78.1M.
  • Braidwell fully exited Guardant Health in Q3 2025, selling an estimated $43.6M.
  • Braidwell's ten largest holdings make up 44% of its $3.37B portfolio in Q3 2025.
  • Braidwell opened 25 new positions and closed 6 in Q3 2025.
  • Braidwell's portfolio value rose 15% quarter-over-quarter to $3.37B.

Based on Braidwell's 13F filing for Q3 2025, filed 14 Nov 2025.